Bayer’s FINE-REAL Study: Real-World Insights on Finerenone Use in CKD and T2D

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting a study titled ‘FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting.’ The study aims to gather real-world data on the use of Finerenone, a drug prescribed for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), to better understand treatment patterns and outcomes.

Intervention/Treatment: The study focuses on the drug Kerendia (Finerenone, BAY94-8862), which is used to block mineralocorticoid receptors, potentially reducing kidney and heart damage in CKD and T2D patients.

Study Design: This observational study follows a cohort model with a prospective time perspective. It involves collecting data from medical records and interviews, focusing on treatment patterns, adverse events, and other medications used alongside Finerenone.

Study Timeline: The study began on June 13, 2022, and is currently recruiting participants. It is expected to conclude in September 2027, with the latest update submitted on July 14, 2025.

Market Implications: The study’s findings could influence Bayer’s stock performance by providing insights into the real-world effectiveness of Finerenone, potentially boosting investor confidence. As the drug is relatively new, positive results could enhance Bayer’s competitive position in the CKD and T2D treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.